Skip to main content

Advertisement

SpringerLink
Log in

Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

We evaluated the effects of the levo (l) enantiomer of amphetamine sulfate on cognitive function in multiple sclerosis (MS) patients. Using a counterbalanced within-subjects design, 19 MS patients received four single-dose administrations of placebo, 15mg, 30mg, or 45 mg of l-amphetamine. Neuropsychological tests measuring processing speed and memory served as the primary outcomes. Performance on tests of processing speed were improved following the 45 mg condition and the largest effects were observed on the Symbol Digit Modalities Test, which measures visual processing speed and working memory. While episodic memory test effects were in the expected direction, the findings were not statistically significant. These preliminary findings show promise for the use of l-amphetamine for the symptomatic treatment of slowed mental processing in MS. Further placebo-controlled trials are needed to confirm these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Benedict R (1997) Brief Visuospatial Memory Test-Revised: Professional manual. Psychological Assessment Resources, Odessa, Florida

  2. Benedict RHB, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock-Guttman B (2006) Validity of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). J Intern Neuropsychol Society 12:549–558

    Google Scholar 

  3. Benedict RHB, Fischer JS, Archibald CJ, Arnett PA, Beatty WW, Bobholz J, Chelune G, Fisk JD, Langdon DW, Caruso LS, Foley FW, LaRocca NG, Vowels L, Weinstein A, DeLuca J, Rao SM, Munschauer FE (2002) Minimal Neuropsychological Assessment of MS Patients: A Consensus Approach. Clin Neuropsychol 16:381–397

    PubMed  Google Scholar 

  4. Bobholz JA, Rao SM (2003) Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 16:283–288

    Article  PubMed  Google Scholar 

  5. DeLuca J, Barbieri-Berger S, Johnson SK (1994) The nature of memory impairments in multiple sclerosis: Aquisition versus retrieval. J Clin Exp Neuropsychol 16:183–189

    Article  PubMed  CAS  Google Scholar 

  6. DeLuca J, Chelune G, Tulsky DS, Lengenfelder J, Chiaravalloti N (2004) Is speed of processing or working memory the primary information processing deficit in multiple sclerosis? J Clin Exp Neuropsychol 26:550–562

    Article  PubMed  Google Scholar 

  7. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB (1996) The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 53:185–188

    PubMed  CAS  Google Scholar 

  8. Greenfield B, Hechman L, Greenfield B, Hechman L (2005) Treatment of attention deficit hyperactivity disorder in adults. Expert Review of Neurotherapeutics 5:107–121

    Article  PubMed  CAS  Google Scholar 

  9. Gronwall DMA (1977) Paced auditory serial addition task: A measure of recovery from concussion. Percept Mot Skills 44:367–373

    PubMed  CAS  Google Scholar 

  10. Heikkila RE, Orlansky H, Mytilineou C, Cohen G, Heikkila RE, Orlansky H, Mytilineou C, Cohen G (1975) Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3Hnorepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Therapeutics 194:47–56

    CAS  Google Scholar 

  11. Jasinski DR, Kovacevi-Ristanovi R, Nickel B, Szelenyi I, Schulze G (1994) Evaluation of physical dependence liability of l-deprenyl (selegiline) in animals. Clin Pharmacol Ther 56:757–767

    Google Scholar 

  12. Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979–1986

    PubMed  CAS  Google Scholar 

  13. Kanbayashi T, Honda K, Kodama T, Mignot E, Nishino S (2000) Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. Neuroscience 99:651–659

    Article  PubMed  CAS  Google Scholar 

  14. Koob GF, Sanna PP, Bloom FE (1998) Neuroscience of addiction. Neuron 21:467–476

    Article  PubMed  CAS  Google Scholar 

  15. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale.Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123

    PubMed  CAS  Google Scholar 

  16. Kuczenski R, Segal DS, Cho AK, Melega W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15:1308–1317

    PubMed  CAS  Google Scholar 

  17. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Ann Neurol 13:227–231

    Article  Google Scholar 

  18. McDonald WI, Compston A, Edan G, Goodkin DE, Hartung H, Lublin F, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley WA, Thompson A, van der Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

    Article  PubMed  CAS  Google Scholar 

  19. Randall DC, Shneerson JM, Plaha KK, File SE (2003) Modafinil affects mood but not cognitive function in healthy young volunteers. Hum Psychopharmacol 18:163–173

    Article  PubMed  CAS  Google Scholar 

  20. Rao SM (1991) A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis

  21. Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691

    PubMed  CAS  Google Scholar 

  22. Reitan RM (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Perceptd Mot Skills 8:271–276

    Google Scholar 

  23. Rey A (1964) L’Examen Clinique en Psychologie. Press Universitaire de France, Paris

  24. Schechter M (1978) Stimulus Properties of d-Amphetamine as compared to l-Amphetamine. Eur J Pharmacol 47:461–464

    Article  PubMed  CAS  Google Scholar 

  25. Segal DS (1975) Behavioral characterization of d- and l-amphetamine: neurochemical implications. Science 190:475–477

    Article  PubMed  CAS  Google Scholar 

  26. Smith A (1982) Symbol digit modalities test:Manual.Western Psychological Services, Los Angeles

  27. Soetens E, Casaer S, D’Hooge R, Hueting JE (1995) Effect of amphetamine on long-term retention of verbal material. Psychopharmacology 119:155–162

    Article  PubMed  CAS  Google Scholar 

  28. Spreen O, Strauss E (1998) A compendium of neuropsychological tests: Administration, norms, and commentary. Oxford University Press, New York

  29. Timar J, Gyrarmati Z, Bama L, Knoll B (1996) Differences in some behavioural effects of deprenyl and amphetamine enantiomers in rats. Physiology and Behavior 60:581–587

    Article  PubMed  CAS  Google Scholar 

  30. Wilken JA, Wallin MT, Sullivan CL, Kane RL, Rossman H, Lawson ME, Simsarian J, Saunders C, Shin R, Mikszewski J, Kerr D, Quig ME (2006) Final analysis of combination therapy (Provigil + Avonex) in the treatment of cognitive problems in patients with relapsing-remitting multiple sclerosis. Mult Scler 12:S114

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology, State University of New York, Buffalo School of Medicine and the Jacobs, Neurological Institute, Buffalo, NY, USA

    R. H. B. Benedict & F. Munschauer

  2. Cognition Pharmaceuticals, New York, NY, USA

    P. Zarevics & D. Erlanger

  3. Albert Einstein, College of Medicine, Bronx, NY, USA

    D. Erlanger

  4. Midamerica Neuroscience Institute, Lenexa, KS, USA

    V. Rowe & T. Feaster

  5. Seaside Therapeutics, Inc, Cambridge, MA

    R. L. Carpenter

  6. Professor of Neurology, Psychiatry and Psychology, Neurology, Suite D6, Buffalo General Hospital, 100 High Street, Buffalo, NY, 14203, USA

    R. H. B. Benedict

Authors
  1. R. H. B. Benedict
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Munschauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Zarevics
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Erlanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Feaster
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. L. Carpenter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. H. B. Benedict.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benedict, R.H.B., Munschauer, F., Zarevics, P. et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol 255, 848–852 (2008). https://doi.org/10.1007/s00415-008-0760-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-0760-7

Key words

Search

Navigation